Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand.
J Sleep Res. 2010 Jun;19(2):366-73. doi: 10.1111/j.1365-2869.2009.00795.x. Epub 2009 Dec 28.
In the present study, we assessed the effects of regular use of methylphenidate medication in children diagnosed with attention deficit hyperactivity disorder (ADHD) on sleep timing, duration and sleep architecture. Twenty-seven children aged 6-12 years meeting diagnostic criteria for Diagnostic and Statistical Manual version IV ADHD and 27 control children matched for age (+/-3 months) and gender. Two nights of standard polysomnographic (PSG) recordings were conducted. ADHD children were allocated randomly to an on- or 48 h off-methylphenidate protocol for first or second recordings. Control children's recordings were matched for night, but no medication was used. Mixed modelling was employed in the analyses so that the full data set was used to determine the degree of medication effects. Methylphenidate in ADHD children prolonged sleep onset by an average of 29 min [confidence interval (CI) 11.6, 46.7], reduced sleep efficiency by 6.5% (CI 2.6, 10.3) and shortened sleep by 1.2 h (CI 0.65, 1.9). Arousal indices were preserved. Relative amounts of stages 1, 2 and slow wave sleep were unchanged by medication. Rapid eye movement sleep was reduced (-2.4%) on the medication night, an effect that became non-significant when control data were incorporated in the analyses. PSG data from ADHD children off-medication were similar to control data. Our findings suggest that methylphenidate reduces sleep quantity but does not alter sleep architecture in children diagnosed with ADHD. An adequate amount of sleep is integral to good daytime functioning, thus the sleep side effects of methylphenidate may affect adversely the daytime symptoms the drug is targeted to control.
在本研究中,我们评估了经常使用哌醋甲酯药物治疗被诊断为注意缺陷多动障碍(ADHD)的儿童对睡眠时间、持续时间和睡眠结构的影响。27 名年龄在 6-12 岁之间符合诊断和统计手册第四版 ADHD 诊断标准的儿童和 27 名年龄(+/-3 个月)和性别匹配的对照组儿童。进行了两晚标准多导睡眠图(PSG)记录。ADHD 儿童被随机分配到使用或不使用哌醋甲酯的方案中进行第一次或第二次记录。对照组儿童的记录与夜间匹配,但不使用药物。在分析中使用混合模型,以便使用完整数据集确定药物影响的程度。哌醋甲酯使 ADHD 儿童的入睡潜伏期平均延长 29 分钟(置信区间 [CI] 11.6,46.7),睡眠效率降低 6.5%(CI 2.6,10.3),睡眠时间缩短 1.2 小时(CI 0.65,1.9)。觉醒指数保持不变。第一、第二和慢波睡眠的相对量不受药物影响。药物治疗夜间快速眼动睡眠减少(-2.4%),当将对照数据纳入分析时,该效果变得不显著。停药后 ADHD 儿童的 PSG 数据与对照数据相似。我们的研究结果表明,哌醋甲酯可减少儿童的睡眠量,但不会改变 ADHD 儿童的睡眠结构。充足的睡眠是良好白天功能的组成部分,因此,哌醋甲酯的睡眠副作用可能会对药物旨在控制的白天症状产生不利影响。